Combined bronchodilator therapy in the management of chronic obstructive pulmonary disease

Respirology

Volumn 2, Issue SUPPL. 1, 1997, Pages

  Friedman, Mitchell ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 adrenergic agonists; Bronchodilator agents; Chronic obstructive pulmonary disease; Combination therapy; Ipratropium bromide

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; SALBUTAMOL;

ALGORITHM; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SCREENING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SMOKING CESSATION;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; IPRATROPIUM; LUNG DISEASES, OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 0030663596     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N. Engl. J. Med. 1987; 317: 1309-14.
2. Gross NJ. COPD: a disease of reversible airflow obstruction. Am. Rev. Respir. Dis. 1986; 133: 725-6.
3. Anthonisen NR, Wright EC and the IPPB Trial Group. Response to inhaled bronchodilators in COPD. Chest 1987; 91: 36S-39S.
4. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV,. J. Am. Med. Assoc. 1994; 272: 1497-505.
5. Vollmer WM, Johnson LR, Buist AS. Relationship of response to a bronchodilator and decline in forced expiratory volume in one second in population studies. Am. Rev. Respir. Dis. 1985; 132: 1186-93.
6. Postma DS, De Vries K, Koeter GH, Sluiter HJ. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long term course of lung function in chronic air-flow obstruction. Am. Rev. Respir. Dis. 1986; 134: 276-80.
7. 7COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994; 105: 1411-19.
8. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in COPD: a retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62-70.
9. Friedman M. Changing practices in COPD: A new pharmacologie treatment algorithm. Cliest 1995; 107: 194S-197S.
10. Epstein SVV, Manning CPR, Ashley MJ, Corey PN. Survey of the clinical use of pressurised aerosol inhalers. Can. Med. Assoc. J. 1979; 120: 813-16.
11. Santa Cruz R, Landa J, Hirsch J, Sackner MA. Trachéal mucous velocity in normal man and patients with obstructive lung disease: effects of terbutaline. Am. Rev. Respir. Dis. 1974; 109: 458-63.
12. Braun SR, McKenzie VVN, Copeland C, Knight L, Ellersieck M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch. Intern. Med .1989; 149: 544-7.
13. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6.
14. Van Schayck CP, Dompeling E, van Herwaarden CLA et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomized controlled study. Br. Med. J. 1991; 303: 1426-31.
15. Gross NJ. Ipratropium bromide. N. Engl. J. Med. 1988; 319: 486-94.
16. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N. Engl. J. Med. 1986; 315: 735-9.
17. Tashkin DP, Ashutosh K, Bleecker ER et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: a 90-day multi-centre study. Am. J. Med. 1986; 81: 81-9.
18. Gross NJ Petty TL, Friedman M, Skorodin MS, Silvers \VG, Donohue JF. Dose response to ipratropium nebulized solution in COPD. A three-centre study. Am. Reu. Respir. Dis. 1989; 139: 1188-91.
19. Hughes JA, Tobin MJ, Bellamy D, Hutchinson DCS. Effect of ipratropium bromide and fenoterol in pulmonary emphysema. Thorax 1982; 37: 667-70.
20. Combination ipratropium bromide/albuterol inhalation solution study group. Routine nebulized ipratropium and albuterol in combination is associated with improved efficacy compared to routine use of either therapy alone in patients with chronic obstructive pulmonary disease. An 85-day multicentre trial. Chest 1997 (in press).
21. Hilleman DE, Wadibia EC, Shinn B. Pharmacoeconomic evaluation of COPD: stratification of outcomes and costs according to initial therapy. Chest 1996; 110: 36S.
22. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann. Intern. Med. 1980; 93: 391-8.
23. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N. Engl. J. Med. 1993; 328: 1017-22.
24. Bone RC. A step-care approach to managing COPD. J. Respir. Dis. 1991; 12: 727-40.